6-K 1 dp71131_6k.htm FORM 6-K

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of December 2016

__________

 

Commission File Number: 001-37891

 

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

 

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland 

Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

X

  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes   No

X

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   No

X

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

AC Immune SA (“AC Immune”) has updated its investor presentation with recent data presented by its partner Genentech, a member of the Roche group, at the 9th Clinical Trials on Alzheimer’s Disease Conference (CTAD) in San Diego. The updated investor presentation and informational poster that summarizes the data are attached hereto as Exhibit 99.1 and 99.2, respectively. From time to time, AC Immune will use this updated presentation and the informational poster in conversations with investors, analysts and others.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number Description
99.1 AC Immune SA Investor Presentation
99.2 Informational Poster

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    AC IMMUNE SA
     
     
      By: /s/ Andrea Pfeifer
        Name: Andrea Pfeifer
        Title: Chief Executive Officer



 

      By: /s/ Martin Velasco
        Name: Martin Velasco
        Title: Chairman

Date: December 15, 2016

 

 

 

EXHIBIT INDEX

 

Exhibit Number Description
99.1 AC Immune SA Investor Presentation
99.2 Informational Poster